The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis

Respiratory Medicine

Volumn 109, Issue 8, 2015, Pages 1058-1062

  Assayag, Deborah ^a   Vittinghoff, Eric ^a   Ryerson, Christopher J ^b   Cocconcelli, Elisabetta ^c   Tonelli, Roberto ^c   Hu, Xiaowen ^d   Elicker, Brett M ^a   Golden, Jeffrey A ^a   Jones, Kirk D ^a   King, Talmadge E ^a   Koth, Laura L ^a   Lee, Joyce S ^a   Ley, Brett ^a   Shum, Anthony K ^a   Wolters, Paul J ^a   Ryu, Jay H ^d   Collard, Harold R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d MAYO CLINIC   (United States)

Author keywords

Bronchodilators; Clinical trials; Idiopathic pulmonary fibrosis; Lung function; Spirometry

Indexed keywords

BRONCHODILATING AGENT; BUDESONIDE; FORMOTEROL; IPRATROPIUM BROMIDE; LEVALBUTEROL; PIRBUTEROL; SALMETEROL; TIOTROPIUM BROMIDE;

AGED; ARTICLE; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; FEMALE; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LONGITUDINAL STUDY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SAMPLE SIZE; SPIROMETRY; CLINICAL TRIAL; DRUG EFFECTS; FOLLOW UP; IDIOPATHIC PULMONARY FIBROSIS; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; VITAL CAPACITY;

AGED; BRONCHODILATOR AGENTS; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; SPIROMETRY; VITAL CAPACITY;

EID: 84938416490     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2015.06.012     Document Type: Article

References (24)

1. R. Pellegrino, and et al. Interpretative strategies for lung function tests Eur. Respir. J. 26 5 2005 948 968
2. M.R. Miller, and et al. Standardisation of spirometry Eur. Respir. J. 26 2 2005 319 338
3. G. Raghu, and et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management Am. J. Respir. Crit. Care Med. 183 6 2011 788 824
4. K.R. Flaherty, and et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia Am. J. Respir. Crit. Care Med. 168 5 2003 543 548
5. H.R. Collard, and et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis Am. J. Respir. Crit. Care Med. 168 5 2003 538 542
6. P.I. Latsi, and et al. Fibrotic idiopathic interstitial pneumonia Am. J. Respir. Crit. Care Med. 168 5 2003 531 537
7. T.E. King, and et al. Analyses of efficacy end points in a controlled trial of interferon-γ1b for idiopathic pulmonary fibrosis CHEST J. 127 1 2005 171 177
8. G. Raghu, and et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis N. Engl. J. Med. 350 2 2004 125 133
9. M. Demedts, and et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis N. Engl. J. Med. 353 21 2005 2229 2242
10. T.E. King, and et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis Am. J. Respir. Crit. Care Med. 184 1 2011 92 99
11. Noble, P.W., et al., Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 377(9779): p. 1760-1769.
12. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis N. Engl. J. Med. 366 21 2012 1968 1977
13. H. Taniguchi, and et al. Pirfenidone in idiopathic pulmonary fibrosis Eur. Respir. J. 35 4 2010 821 829
14. C.E. Daniels, and et al. Imatinib treatment for idiopathic pulmonary fibrosis Am. J. Respir. Crit. Care Med. 181 6 2010 604 610
15. L. Richeldi, and et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis N. Engl. J. Med. 365 12 2011 1079 1087
16. H.R. Collard, and et al. Burden of illness in idiopathic pulmonary fibrosis J. Med. Econ. 15 5 2012 829 835
17. C.J. Ryerson, and et al. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis CHEST J. 144 1 2013 234 240
18. M. Mejía, and et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension CHEST J. 136 1 2009 10 15
19. V. Cottin, and et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity Eur. Respir. J. 26 4 2005 586 593
20. American Thoracic Society Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS) Am. J. Respir. Crit. Care Med. 161 2 Pt 1 2000 646 664
21. M.R. Miller, and et al. Standardisation of spirometry Eur. Respir. J. 26 2 2005 319 338
22. Global Strategy for Diagnosis, M., and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2015 2015
23. B. Ley, and et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis Ann. Intern. Med. 156 10 2012 684 691
24. B. Ley, and et al. Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis Eur. Respir. J. 45 5 2015 1374 1378